代表性论文：
1) Song L, Qi G, Shi W, Zeng Q, Qin Y, Wang Z, Li W, Song Z, Zhang A*, Lu H*. A universal Fab-Fc masked cytokine prodrug platform: αPD-L1/IL-15 prodrug activates CD44+CD8+ T cells in tumor-draining lymph nodes to enhance antitumor immunity. J ImmunoTher Cancer.2025 Jul 31; 13(7):e011944. Doi: 10.1136/jitc-2025-011944。
2) Shi W#, Xu W#, Song L, Zeng Q, Qi G, Qin Y, Li Z, Liu X, Jiao Z, Zhao Y, Liu N*, Lu H*. A tumor-conditional IL-15 safely synergizes with immunotherapy to enhance antitumor immune responses. Mol Ther 2024 Dec 4;32(12):4482-4496. Doi: 10.1016/j.ymthe.2024.10.021
3) Shi W, Liu N, Liu Z, Yang Y, Zeng Q, Wang Y, Song L, Hu F, Fu J, Chen J, Wu M, Zhou L, Zhu F, Gong L, Zhu J, Jiang L*, Lu H*. Next-generation anti-PD-L1/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity. Cell Reports Medicine. 2024 May 21;5(5):101531. Doi: 10.1016/j.xcrm.2024.101531.
4) Zhu W, Wang Y, Lv L, Wang H, Shi W, Liu X, Zhou M, Zhu J, Lu H*. Universal chimeric Fcγ receptor T cells with appropriate affinity for IgG1 antibody exhibit optimal antitumor efficacy. Acta Pharm Sin B. 2023 May 13(5): 2071-2085. Doi:10.1016/j.apsb.2023.02.004.
5) Shi W, Lv L, Liu N, Wang H, Wang Y, Zhu W, Liu Z, Zhu J, Lu H*. A novel anti-PD-L1/IL-15 immunocytokine overcomes resistance to PD-L1 blockade and elicits potent antitumor immunity. Mol Ther. 2023 Jan 4;31(1):66-77. DOI: 10.1016/j.ymthe.2022.08.016.
6) Lv L, Wang H, Shi W, Wang Y, Zhu W, Liu Z, Chen X, Zheng C, Kong W, Li W, Zhu J, Lu H*. A homodimeric IL-15 superagonist F4RLI with easy preparation, improved half-life, and potent antitumor activities. Appl Microbiol Biotechnol. 2022 Nov;106(21):7039-7050. Doi: 10.1007/s00253-022-12209-1.
7) Zhu W, Wang Y, Lv L, Wang H, Shi W, Liu Z, Yang W, Zhu J, Lu H*. SHTXTHHly, an extracellular secretion platform for the preparation of bioactive peptides and proteins in Escherichia coli. Microb Cell Fact. 2022 Jun 27;21(1):128. DOI: 10.1186/s12934-022-01856-8.
8) Zhao M, Luo M, Xie Y, Jiang H, Cagliero C, Li N, Ye H, Wu M, Hao S, Sun T, Yang H, Zhang M, Lin T, Lu H*, Zhu J*. Development of a recombinant human IL-15·sIL-15Rα/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model. Biomedicine & Pharmacotherapy. 2019 Feb 21;112:108677. Doi: 10.1016/j.biopha.2019.108677.
9) Lu H, Zhu S, Qian L, Xiang D, Zhang W, Nie A, Gao J, Wu M, Gao J, Lu B, Yu Y, Han W, Moldenhauer A. Activated expression of the chemokine Mig after chemotherapy contributes to chemotherapy-induced bone marrow suppression and lethal toxicity. Blood 2012; May 24;119(21):4868-77. Doi: 10.1182/blood-2011-07-367581.
